Value-Based Agreements in Rare Disease: Focus on Hereditary Amyloid Transthyretin Amyloidosis

.navbar .collapse { display: block; } .mobile-nav { max-height: none !important; } @media screen and (min-width: 1200px) { .navbar #basic-navbar-nav .navbar-nav { position: static !important; } }

Value-Based Agreements in Rare Disease: Focus on Hereditary Amyloid Transthyretin Amyloidosis

January 27, 2021

Supplements and Featured Publications, Value-Based Agreements in Rare Disease: Focus on Hereditary Amyloid Transthyretin Amyloidosis,

The American Journal of Managed Care^® hosted a scientific interchange titled “Value-Based Agreements in Rare Disease” on September 30, 2020. This publication highlights key discussion points and insights from this event.